Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Renal Cell 11Melanoma 10Carcinoma, Hepatocellular 7Brain Neoplasms 6Leukemia, Myeloid, Acute 5Glioblastoma 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelomonocytic, Acute 4Gliosarcoma 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Thyroid Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Liver Neoplasms 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Hemangiosarcoma 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Blast Crisis 3

Interventions

Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Familial medullary thyroid carcinoma × Sorafenib × Clear all
NCT00390325 2024-02-06

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 15 charts
EndocrineHead & Neck

Familial medullary thyroid carcinoma, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡